Black Rock Inc. Pyxis Oncology, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,785,895 shares of PYXS stock, worth $4.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,785,895

Previous 321,665 766.09%

Holding current value

$4.65 Million

Previous $1.37 Million 573.07%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$3.06 - $5.58 $7.54 Million - $13.8 Million	2,464,230 Added 766.09%	2,785,895 $9.22 Million
Q1 2024 May 10, 2024	BUY	$2.03 - $6.59 $22,466 - $72,931	11,067 Added 3.56%	321,665 $1.37 Million
Q4 2023 Feb 13, 2024	BUY	$1.4 - $2.09 $12,717 - $18,985	9,084 Added 3.01%	310,598 $559,000
Q3 2023 Nov 13, 2023	BUY	$1.6 - $2.78 $52,923 - $91,954	33,077 Added 12.32%	301,514 $600,000
Q2 2023 Aug 11, 2023	BUY	$2.46 - $4.07 $138,126 - $228,526	56,149 Added 26.45%	268,437 $687,000
Q1 2023 May 12, 2023	BUY	$1.38 - $6.0 $1,319 - $5,736	956 Added 0.45%	212,288 $851,000
Q4 2022 Feb 13, 2023	BUY	$1.14 - $2.0 $5,446 - $9,556	4,778 Added 2.31%	211,332 $283,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $3.03 $2,350 - $3,787	1,250 Added 0.61%	206,554 $406,000
Q2 2022 Aug 12, 2022	SELL	$2.02 - $4.53 $637,505 - $1.43 Million	-315,597 Reduced 60.59%	205,304 $489,000
Q1 2022 May 12, 2022	BUY	$4.04 - $11.43 $28,494 - $80,615	7,053 Added 1.37%	520,901 $2.1 Million
Q4 2021 Feb 10, 2022	BUY	$8.39 - $13.64 $4.31 Million - $7.01 Million	513,848 New	513,848 $5.64 Million

Others Institutions Holding PYXS

# of Institutions

101

Shares Held

28.2M

Call Options Held

539K

Put Options Held

54.1K

View Full List

About Pyxis Oncology, Inc.

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $58.6M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

More about PYXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account